Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company’s Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
“We are very pleased to welcome Tim to our Board. Tim is an industry veteran with decades of strong strategic and financial experience in the life sciences industry,” saidWerner Cautreels, PhD, Chairman, CEO and President of Selecta Biosciences. “Tim’s exceptional grasp of the commercial and financial opportunities and challenges entailed in financing and growing Selecta will add significant strategic perspectives as we seek to advance candidates from Selecta’s pipeline portfolio in development.”
“I am very excited to be joining Selecta’s Board of Directors at this pivotal time as the company applies its novel technologies to generate a robust pipeline of candidates,” said Mr. Barabe. “Selecta’s novel immune therapies offer significant opportunities for the company to provide patients, providers and payors with meaningful new treatment options to address rare and serious diseases.”
Mr. Barabe has more than 30 years of experience in the life sciences industry. He served as the chief financial officer and executive vice president at Affymetrix Inc., where he led the company’s financial functions as well as the treasury, investor relations, and information technology departments. Previously, he served as senior vice president and chief financial officer at Human Genome Sciences, where he was responsible for working with the leadership team to drive the financial strategy and operations of the company. For more than 20 years, he held senior international executive roles in finance, general management, and strategic planning at Novartis AG, one of the world’s largest pharmaceutical companies. His roles included chief financial officer of the Sandoz Generics Business Unit, president of the CIBA Vision Corporation Specialty Lens Business Franchise, and group vice president and chief financial officer of CIBA Vision Corporation. Mr. Barabe has a B.B.A. in Finance from the University of Massachusetts (Amherst) and an M.B.A. from the University of Chicago. He also serves as a director of several public company boards, including ArQule, Opexa Therapeutics and Vigilant Biosciences.